These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31701648)

  • 1. Hypophysitis on immunotherapy with checkpoint inhibitors.
    Jäger IM; Kohlmann J; Simon JC; Sandner B; Tönjes A; Ziemer M
    J Dtsch Dermatol Ges; 2019 Nov; 17(11):1168-1170. PubMed ID: 31701648
    [No Abstract]   [Full Text] [Related]  

  • 2. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
    Miller AH; Brock P; Jim Yeung SC
    Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
    Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitor-Associated Hypophysitis.
    Chang LS; Yialamas MA
    J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
    [No Abstract]   [Full Text] [Related]  

  • 7. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
    Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
    Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
    Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB; Bastholt L; Yderstræde K
    Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
    Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
    J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
    Deligiorgi MV; Liapi C; Trafalis DT
    Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].
    Faviez G; Bousquet E; Rabeau A; Rouquette I; Collot S; Goumarre C; Meyer N; Prevot G; Mazieres J
    Rev Mal Respir; 2018 Nov; 35(9):963-967. PubMed ID: 30220489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer immunotherapy-associated hypophysitis.
    Castillero F; Castillo-Fernández O; Jiménez-Jiménez G; Fallas-Ramírez J; Peralta-Álvarez MP; Arrieta O
    Future Oncol; 2019 Sep; 15(27):3159-3169. PubMed ID: 31423850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma.
    Comstock DE; Nishino M; Giardino AA
    JAMA Oncol; 2017 May; 3(5):703-704. PubMed ID: 28196215
    [No Abstract]   [Full Text] [Related]  

  • 16. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
    Mirza S; Hill E; Ludlow SP; Nanjappa S
    Melanoma Res; 2017 Jun; 27(3):271-273. PubMed ID: 28146044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
    Grätz V; Langan EA; Neumann A; Zillikens D; Terheyden P
    Melanoma Res; 2019 Oct; 29(5):516-521. PubMed ID: 30870272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings.
    Singh D; Hsu CC; Kwan GN; Bhuta S
    Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.